Solid Biosciences Inc (NASDAQ:SLDB) has been assigned a consensus rating of “Hold” from the nine brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $45.14.
Several research analysts have recently commented on SLDB shares. Zacks Investment Research upgraded Solid Biosciences from a “hold” rating to a “buy” rating and set a $36.00 target price for the company in a research report on Wednesday, October 17th. Credit Suisse Group started coverage on Solid Biosciences in a research report on Thursday, September 6th. They issued a “neutral” rating and a $38.00 target price for the company.
A number of large investors have recently added to or reduced their stakes in the stock. Matisse Capital acquired a new position in Solid Biosciences during the 3rd quarter valued at approximately $382,000. Northern Trust Corp boosted its position in Solid Biosciences by 21.2% during the 2nd quarter. Northern Trust Corp now owns 111,215 shares of the company’s stock valued at $3,963,000 after purchasing an additional 19,442 shares during the period. Bank of New York Mellon Corp boosted its position in Solid Biosciences by 58.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 31,889 shares of the company’s stock valued at $1,137,000 after purchasing an additional 11,726 shares during the period. Partner Fund Management L.P. acquired a new position in Solid Biosciences during the 2nd quarter valued at approximately $16,724,000. Finally, Partner Investment Management L.P. acquired a new position in Solid Biosciences during the 2nd quarter valued at approximately $134,000. Institutional investors and hedge funds own 60.14% of the company’s stock.
Solid Biosciences (NASDAQ:SLDB) last issued its earnings results on Friday, August 10th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.01). Research analysts expect that Solid Biosciences will post -2.21 earnings per share for the current year.
About Solid Biosciences
Solid Biosciences Inc engages in identifying and developing therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles. The company's product candidates also comprise SB-001, a monoclonal antibody to reduce fibrosis and inflammation.
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.